IGF1
Overview
IGF1 (insulin-like growth factor 1) encodes a growth factor that signals through IGF1R to promote cell proliferation and survival. In cancer pharmacogenomics, high IGF1 expression in multiple myeloma cell lines strongly predicts sensitivity to IGF-1R inhibitors, providing a rationale for IGF-1R-targeted therapy in this lineage.
Alterations observed in the corpus
- High IGF1 expression in multiple myeloma cell lines correlates with IGF-1R inhibitor (AEW541) sensitivity in the CCLE pharmacogenomic profiling of 947 cancer cell lines PMID:22460905
- Established EWS::FLI1 transcriptional target induced upon oncogene expression in heMSCs; validated by RT-qPCR as part of the Ewing sarcoma gene expression program PMID:25186949
Cancer types (linked)
- MM (multiple myeloma): High IGF1 expression is lineage-enriched and correlates with enhanced AEW541 (IGF-1R inhibitor) sensitivity, supporting multiple myeloma as a promising indication for IGF-1R-targeted clinical trials PMID:22460905
Co-occurrence and mutual exclusivity
- IGF1 and IGF1R are co-expressed at high levels in multiple myeloma cell lines, both contributing to AEW541 sensitivity as independent predictive features PMID:22460905
Therapeutic relevance
- High IGF1 expression predicts sensitivity to AEW541 (IGF-1R inhibitor) in the CCLE; multiple myeloma is highlighted as a promising indication for IGF-1R inhibitor clinical trials based on IGF1/IGF1R co-expression PMID:22460905
Open questions
- Whether IGF1 expression level in primary multiple myeloma tumours predicts clinical response to IGF-1R inhibitors as well as it does in CCLE cell lines requires prospective validation.
Sources
This page was processed by entity-page-writer on 2026-05-06. - PMID:25186949
This page was processed by wiki-cli on 2026-05-11.